0001209191-18-053540.txt : 20181002
0001209191-18-053540.hdr.sgml : 20181002
20181002214201
ACCESSION NUMBER: 0001209191-18-053540
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180928
FILED AS OF DATE: 20181002
DATE AS OF CHANGE: 20181002
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Topper James N
CENTRAL INDEX KEY: 0001341382
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38670
FILM NUMBER: 181103630
MAIL ADDRESS:
STREET 1: 550 HAMILTON AVENUE, SUITE 100
CITY: PALO ALTO
STATE: CA
ZIP: 94301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Entasis Therapeutics Holdings Inc.
CENTRAL INDEX KEY: 0001724344
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 824592913
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 GATEHOUSE DRIVE
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: (781) 810-0120
MAIL ADDRESS:
STREET 1: 35 GATEHOUSE DRIVE
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: Entasis Therapeutics Ltd
DATE OF NAME CHANGE: 20171204
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-09-28
0
0001724344
Entasis Therapeutics Holdings Inc.
ETTX
0001341382
Topper James N
C/O ENTASIS THERAPEUTICS HOLDINGS INC.
35 GATEHOUSE DRIVE
WALTHAM
MA
02451
1
0
1
0
Common Stock
2018-09-28
4
C
0
337707
A
337707
I
See Footnote
Common Stock
2018-09-28
4
C
0
251487
A
589194
I
See Footnote
Common Stock
2018-09-28
4
C
0
320898
A
974066
I
See Footnote
Common Stock
2018-09-28
4
P
0
375887
15.00
A
1349953
I
See Footnote
Series B Convertible Preferred Stock
2018-09-28
4
C
0
7000000
0.00
D
Common Stock
337707
0
I
See Footnote
Series B-1 Tranche A Convertible Preferred Stock
2018-09-28
4
C
0
5212833
0.00
D
Common Stock
251487
0
I
See Footnote
Series B-1 Tranche B Convertible Preferred Stock
2018-09-28
4
C
0
6651574
0.00
D
Common Stock
320898
0
I
See Footnote
Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. The Reporting Person, a director of the Issuer, is a managing member of FHM LLC. The Reporting Person disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his pecuniary interest in such shares.
This number includes an aggregate of 63,974 shares of Common Stock received upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018.
/s/ Jason Minio, Attorney-in-Fact
2018-10-02